US Residents Only

Download Enrollment Form

For U.S. Audiences Only

The power to do more

Faced with Hutchinson-Gilford progeria syndrome (progeria) and processing-deficient progeroid laminopathies (PDPL)? Know Zokinvy® is the first and only disease-modifying treatment for these ultra-rare diseases.1,2

Prescribe Now

Michiel, 21 and Amber, 13, Belgium. Photo courtesy of The Progeria Research Foundation.

Zokinvy targets a key step in the disease pathophysiology for progeria and PDPL1,2

See How
Piano
Pills

Starting and staying on Zokinvy matters

Eiger OneCare provides patients and caregivers with a dedicated, personalized support team to help with insurance coverage investigation, financial support options, and connecting with the Zokinvy pharmacy.

Learn More

IMPORTANT SAFETY INFORMATION

Contraindications

ZOKINVY is contraindicated in patients taking:

  • Strong or moderate CYP3A inhibitors or inducers
  • Midazolam
  • Lovastatin, simvastatin, and atorvastatin

Warnings and Precautions

Laboratory Abnormalities

Some patients treated with ZOKINVY developed laboratory abnormalities. These included:

  • Electrolyte abnormalities (43%), such as hyperkalemia, hypokalemia, hyponatremia, or hypercalcemia
  • Myelosuppression (35%), such as reductions in absolute neutrophil count, white blood cell counts, lymphopenia, hemoglobin, or hematocrit
  • Increased liver enzymes, such as aspartate aminotransferase (35%), or alanine aminotransferase (27%)

These laboratory abnormalities often improved while continuing ZOKINVY, but it is not possible to exclude ZOKINVY as a cause of the abnormalities. Periodically monitor electrolytes, complete blood counts, and liver enzymes, and manage abnormalities accordingly.

Nephrotoxicity
  • Lonafarnib caused nephrotoxicity in rats at plasma drug exposures approximately equal to that achieved with the human dose. Monitor renal function at regular intervals during ZOKINVY therapy.
Retinal Toxicity
  • Lonafarnib caused rod-dependent, low-light vision decline in monkeys at plasma drug exposures similar to that achieved with the human dose. Perform ophthalmological evaluation at regular intervals and at the onset of any new visual changes during ZOKINVY therapy.
Impaired Fertility
  • Based on findings in rats Zokinvy may reduce fertility. Advise males and females of reproducitve potential of the animal findings and that the impact on pubertal development and the potential for impaired fertility with Zonkivy have not been adequately evaluated.
Adverse Reactions
  • The most common adverse reactions were vomiting (90%), diarrhea (81%), infection (78%), nausea (56%), decreased appetite (53%), fatigue (51%), upper respiratory tract infection (51%), abdominal pain (48%), musculoskeletal pain (48%), electrolyte abnormalities (43%), headache (37%), decreased weight (37%), increased aspartate aminotransferase (35%), myelosuppression (35%), cough (33%), decreased blood bicarbonate (33%), hypertension (29%), and increased alanine aminotransferase (27%).
Gastrointestinal Adverse Reactions
  • Gastrointestinal adverse reactions were the most frequently reported adverse reactions. Of the 57 patients (90%) that experienced vomiting, 30 (53%) patients had mild vomiting, 26 (46%) patients had moderate vomiting, and 1 (2%) patient had severe vomiting.
  • Of the 35 patients (56%) that experienced nausea, 34 (97%) patients had mild nausea and 1 (3%) patient had moderate nausea.
  • Of the 51 patients (81%) that experienced diarrhea, the majority of patients (92%) experienced mild or moderate diarrhea; 38 (75%) patients reported mild diarrhea and 9 (18%) patients reported moderate diarrhea. Four (8%) patients reported severe diarrhea.
  • Loss of fluids and dehydration can be severe, leading to hospitalization. As a result, patients should receive therapy for diarrhea at the earliest signs in order to avoid possible severe complications.
Alanine Aminotransferase and Aspartate Aminotransferase Elevations
  • Increased alanine aminotransferase was commonly reported (17 [27%] patients). Of the 17 patients with increased alanine aminotransferase, 14 (82%) patients had mild increases, 1 (6%) patient had moderate increases, and 2 (12%) patients had severe increases.
  • Increased aspartate aminotransferase was also commonly reported (22 [35%] patients). Of the 22 patients with increased aspartate aminotransferase, 21 (95%) patients had mild increases and 1 (5%) patient had a severe increase.
Hypertension
  • Increases in blood pressure have been documented in patients treated with ZOKINVY. In clinical trials the incidence of hypertension was 8.1%.
Drug Interactions
  • Strong or moderate CYP3A inhibitors
    • ZOKINVY administration with strong or moderate CYP3A inhibitors, including herbal supplements can increase exposures of ZOKINVY resulting in risk of clinically significant adverse events.
      • Do not mix the contents of ZOKINVY with any food or juice containing grapefruit or Seville oranges.
  • Weak CYP3A inhibitors
    • Avoid coadmistration of Zokinvy with weak CYP3A inhibitors. If coadministration is unavoidable, reduce ZOKINVY dosage. Resume previous dosage 14 days after discontinuing the weak CYP3A inhibitor. Closely monitor patients for arrhythmias and events such as syncope and heart palpitations.
  • Strong or moderate CYP3A inducers
    • ZOKINVY administration with CYP3A inducers, including herbal supplements, can decrease exposure of ZOKINVY, which may impact efficacy.
  • CYP2C9 Inhibitors
    • Avoid coadministration of Zokinvy with CYP2C9 inhibitors. If coadminstration is unavoidable, closely monitor patients for arrhythmias and events such as syncope and heart palpitations because the effect of increased Zokinvy exposures on the QT interval is unknown.
  • Certain CYP3A substrates
    • When ZOKINVY is coadministered with certain CYP3A substrates where minimal concentration changes may lead to serious or life-threatening toxicities, monitor for adverse reactions and reduce the dosage of the CYP3A substrate in accordance with its approved product labeling.
  • Loperamide
    • Lonafarnib is a weak inhibitor of P-gp and strong inhibitor of CYP3A. Do not exceed loperamide 1 mg once daily when first coadministered with ZOKINVY. Slowly increase loperamide dosage with caution as needed to treat diarrhea in accordance with its approved product labeling.
  • CYP2C19 substrates
    • Lonafarnib is a moderate CYP2C19 inhibitor. Avoid coadministration of ZOKINVY with CYP2C19 substrates. If coadministration is unavoidable, monitor for adverse reactions and reduce the dosage of the CYP2C19 substrate in accordance with its approved product labeling.

Use in Specific Populations

Patients who are pregnant or lactating: Based on findings from animal studies, ZOKINVY can cause embryofetal harm. There are no human data on ZOKINVY use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Advise females of reproductive potential to use effective contraception during treatment with ZOKINVY. There are no data on the presence of ZOKINVY in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZOKINVY and any potential adverse effects of the breastfed infant from ZOKINVY or from the underlying maternal condition.

To report SUSPECTED ADVERSE REACTIONS, contact Eiger BioPharmaceuticals, Inc. at 833-267-0545 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information.

References:

  • 1. Zokinvy [package insert]. Palo Alto, CA: Eiger BioPharmaceuticals Inc; 2020. 2. Gordon LB, Shappell H, Massaro J, et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. JAMA. 2018;319(16):1687-1695. doi:10.1001/jama.2018.3264.

INDICATION AND USAGE

ZOKINVY is indicated in adult and pediatric patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above:

  • To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS)
  • For the treatment of processing-deficient Progeroid Laminopathies with either:
    • Heterozygous LMNA mutation with progerin-like protein accumulation
    • Homozygous or compound heterozygous ZMPSTE24 mutations

Limitations of Use

ZOKINVY is not indicated for use in patients with non-HGPS Progeroid Syndromes or with Progeroid Laminopathies known to be processing-proficient. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.

Image

IMPORTANT SAFETY INFORMATION

Contraindications

ZOKINVY is contraindicated in patients taking:

  • Strong or moderate CYP3A inhibitors or inducers
  • Midazolam
  • Lovastatin, simvastatin, and atorvastatin

INDICATION AND USAGE

ZOKINVY is indicated in adult and pediatric patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above:

  • To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS)
  • For the treatment of processing-deficient
+
You are now leaving
Zokinvy.com

Eiger has not reviewed the content on the following website for accuracy or completeness.

Cancel Continue